GCM
LRMR icon

Graham Capital Management’s Larimar Therapeutics LRMR Stock Holding History

Graham Capital Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$155K Sell
34,438
-7,817
-18% -$31.2K ﹤0.01% 995
2025
Q4 		$161K Buy
+42,255
New +$164K ﹤0.01% 1087
2025
Q1 		– Sell
-14,078
Closed -$54.5K – 1415
2024
Q4 		$54.5K Buy
+14,078
New +$92.9K ﹤0.01% 1177

Other funds holding LRMR

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Graham Capital Management's LRMR Position: Q1 2026 in Review

Graham Capital Management reduced its Larimar Therapeutics (LRMR) stake by 18% in Q1 2026, selling an estimated $31.2K and leaving 34,438 shares worth $155K. The position accounts for ﹤0.01% of the portfolio, ranked #995.

Graham Capital Management first reported a position in LRMR in Q4 2024 and has held it in 3 quarters since. The position peaked at $161K in Q4 2025. 162 funds tracked by Wall St. Rank hold LRMR as of Q1 2026.

  • Graham Capital Management held 34,438 shares of Larimar Therapeutics worth $155K as of Q1 2026.
  • Graham Capital Management sold 7,817 Larimar Therapeutics shares in Q1 2026, an estimated $31.2K.
  • Larimar Therapeutics made up ﹤0.01% of Graham Capital Management's portfolio in Q1 2026, its #995 holding.
  • Graham Capital Management first reported a position in Larimar Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • Graham Capital Management's Larimar Therapeutics position peaked at $161K in Q4 2025.
  • 162 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.